The considerable variability in the warfarin dose–response relationship between individuals,
is explained mainly by genetic variation in its major metabolic (CYP2C9) and target (…

… At 15 weeks, hypothyroidism was severe (see Table 1), and L-thyroxine supplements
were started at 50 μg/d and raised at 21 weeks to 86 μg/d. Thyroid hormone levels gradually …

Well‐characterized genes that affect warfarin metabolism (cytochrome P450 (CYP) 2C9)
and sensitivity (vitamin K epoxide reductase complex 1 (VKORC1)) explain one‐third of the …

We examined the influence of combined genotypes on interindividual variability in warfarin
dose-response. In 100 anticoagulated patients we quantified the effects of polymorphisms in: …

Background: Privacy restrictions limit access to protected patient-derived health information
for research purposes. Consequently, data anonymization is required to allow researchers …

Evidence for the association between hypomagnesemia and proton pump inhibitors (PPIs),
highlighted by the 2011 FDA Drug Safety Communication, rests mainly on studies in …

Background : Oral methotrexate and folic acid are partly absorbed by a common intestinal
transporter. Aim : To determine the relative bioavailability of oral low‐dose methotrexate …

The neurotransmitter acetylcholine (ACh) plays a critical role in brain circuits mediating motor
control, attention, learning and memory. Cholinergic dysfunction is associated with multiple …

… in the general population, c GDM variants and d glycaemic trait variants in pregnant women
… (C1431T), that is in weak linkage disequilibrium with rs1801282 (D’=0.68, R 2 =.42) was …

… Author links open overlay panel Yael Zenziper Straichman a f , Daniel Kurnik a d , Ilan Matok
f , Hillel … Daniel Kurnik contributed to study design, data collection, statistical analysis, and …